![Long-term azithromycin for Indigenous children with non-cystic-fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double-blind, randomised controlled trial - The Lancet Respiratory Medicine Long-term azithromycin for Indigenous children with non-cystic-fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double-blind, randomised controlled trial - The Lancet Respiratory Medicine](https://www.thelancet.com/cms/attachment/2098740838/2078832734/gr1.gif)
Long-term azithromycin for Indigenous children with non-cystic-fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double-blind, randomised controlled trial - The Lancet Respiratory Medicine
![JCM | Free Full-Text | Current Challenges in Chronic Bronchial Infection in Patients with Chronic Obstructive Pulmonary Disease JCM | Free Full-Text | Current Challenges in Chronic Bronchial Infection in Patients with Chronic Obstructive Pulmonary Disease](https://pub.mdpi-res.com/jcm/jcm-09-01639/article_deploy/html/images/jcm-09-01639-ag-550.jpg?1592806940)
JCM | Free Full-Text | Current Challenges in Chronic Bronchial Infection in Patients with Chronic Obstructive Pulmonary Disease
![Short- and long-term impacts of azithromycin treatment on the gut microbiota in children: A double-blind, randomized, placebo-controlled trial - eBioMedicine Short- and long-term impacts of azithromycin treatment on the gut microbiota in children: A double-blind, randomized, placebo-controlled trial - eBioMedicine](https://www.thelancet.com/cms/attachment/d426eccb-fcde-445d-a7fd-ac3791954751/gr1_lrg.jpg)
Short- and long-term impacts of azithromycin treatment on the gut microbiota in children: A double-blind, randomized, placebo-controlled trial - eBioMedicine
![Efficacy of azithromycin in severe asthma from the AMAZES randomised trial | European Respiratory Society Efficacy of azithromycin in severe asthma from the AMAZES randomised trial | European Respiratory Society](https://openres.ersjournals.com/content/erjor/5/4/00056-2019/F1.large.jpg)
Efficacy of azithromycin in severe asthma from the AMAZES randomised trial | European Respiratory Society
![What is the evidence for using macrolide antibiotics to treat COVID-19? - The Centre for Evidence-Based Medicine What is the evidence for using macrolide antibiotics to treat COVID-19? - The Centre for Evidence-Based Medicine](https://www.cebm.net/wp-content/uploads/2020/04/macrolide.jpg)
What is the evidence for using macrolide antibiotics to treat COVID-19? - The Centre for Evidence-Based Medicine
Global Initiative for Chronic Obstructive Lung Disease Global Initiative for Chronic Obstructive Lung Disease
![Long term effects of azithromycin in patients with cystic fibrosis: a double blind, placebo controlled trial | Thorax Long term effects of azithromycin in patients with cystic fibrosis: a double blind, placebo controlled trial | Thorax](https://thorax.bmj.com/content/thoraxjnl/61/10/895/F1.large.jpg)
Long term effects of azithromycin in patients with cystic fibrosis: a double blind, placebo controlled trial | Thorax
![The impact of long-term azithromycin on antibiotic resistance in HIV-associated chronic lung disease | European Respiratory Society The impact of long-term azithromycin on antibiotic resistance in HIV-associated chronic lung disease | European Respiratory Society](https://openres.ersjournals.com/content/erjor/8/1/00491-2021/F1.large.jpg)
The impact of long-term azithromycin on antibiotic resistance in HIV-associated chronic lung disease | European Respiratory Society
![Benefit–harm analysis of azithromycin for the prevention of acute exacerbations of chronic obstructive pulmonary disease | Thorax Benefit–harm analysis of azithromycin for the prevention of acute exacerbations of chronic obstructive pulmonary disease | Thorax](https://thorax.bmj.com/content/thoraxjnl/77/11/1079/F1.large.jpg)
Benefit–harm analysis of azithromycin for the prevention of acute exacerbations of chronic obstructive pulmonary disease | Thorax
![Mechanism of action, resistance, synergism, and clinical implications of azithromycin - Heidary - 2022 - Journal of Clinical Laboratory Analysis - Wiley Online Library Mechanism of action, resistance, synergism, and clinical implications of azithromycin - Heidary - 2022 - Journal of Clinical Laboratory Analysis - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/8fe08ad8-513a-42e2-970b-0135867134b5/jcla24427-fig-0002-m.jpg)
Mechanism of action, resistance, synergism, and clinical implications of azithromycin - Heidary - 2022 - Journal of Clinical Laboratory Analysis - Wiley Online Library
![Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial - The Lancet Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial - The Lancet](https://www.thelancet.com/cms/asset/2ffb2e5b-9e76-4765-a065-5fab6b80633d/gr1.jpg)